Dr. Lal Path Labs Ltd. has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs has informed the exchanges that its Board of Directors will meet on Thursday, April 30, 2026, to consider and approve the audited financial results (both standalone and consolidated) for the fourth quarter and full financial year ending March 31, 2026. In line with SEBI's insider trading regulations and the company's own internal code, the trading window for dealing in the company's shares has been closed from April 1, 2026, to May 2, 2026, covering both days. This means directors, employees and other designated persons cannot trade in the stock during this period. The filing is a routine compliance disclosure under SEBI LODR regulations and is not material on its own.
No direct impact on the stock; this is a standard regulatory filing ahead of the full-year earnings announcement. Retail investors should mark April 30, 2026 as the likely date for the FY26 results and watch for any guidance or dividend declaration that may emerge from the board meeting.